New Typhoid Vaccine Could Help Reduce Threats Posed By Antimicrobial Resistance

STAT: A new vaccine against typhoid fever will also help fight antimicrobial resistance
Seth Berkely, CEO of Gavi, the Vaccine Alliance

“…Until relatively recently, antibiotics were a major part of the solution in the fight against typhoid fever. … But through the widespread overuse and misuse of antibiotics, the typhoid-causing pathogen has developed resistance to multiple drugs. … The solution to this problem is to prevent typhoid fever in the first place. … [The typhoid conjugate vaccine (TCV) is] one of the most widely anticipated vaccines … Demand for the vaccine is expected to be high. Not just because TCV should save three lives for every 10,000 doses administered, but also because of the significant role it will play in reducing the growing threats posed by antimicrobial resistance, and the associated economic burden it brings. … With an estimated 50 million doses of antibiotics prescribed for typhoid every year, one solution is simple: prevent the disease in the first place through vaccination and continued improvements in water and sanitation” (11/30).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.